On August 18, 2025, Biodexa Pharmaceuticals Plc announced the enrollment of the first two patients in their pivotal Phase 3 Serenta trial for eRapa, aimed at treating familial adenomatous polyposis. This event is significant for the company as it marks a key milestone in their clinical trial process.